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Abstract  
 
Background: Alzheimer's disease (AD) is the most common cause of dementia that is an irretrievable chronic 
neurodegenerative disease. In the current study, we have examined the therapeutic effects of Iris germanica extract on 
Amyloid β (Aβ) induced memory impairment.  
Materials and Methods: Wistar rats were divided into five groups of 8 per each. Groups were as followed: control 
group which were normal rats without induction of AD, Aβ group which received Aβ (50 ng/side), iris 100 group 
which received Aβ + Iris (100 mg/kg), iris 200 group which received Aβ + Iris (200 mg/kg), and iris 400 group which 
received Aβ + Iris (400 mg/kg). AD was established by intrahippocampal injection of 50 ng/μl/side Aβ1-42. The day 
after surgery, animals in treatment groups received different doses of the aqueous extract of Iris by gavage for 30 days. 
Morris water maze test (MWM) was performed to assess the effects of I. germanica on learning and memory of rats 
with Aβ induced AD.  
Results: Data from MWM tests, including escape latency and traveled distance, demonstrated that I. germanica extract 
could markedly improve spatial memory in comparison to control. Moreover, the plant had a significantly better effect 
on the performance of AD rats in the probe test.  
Conclusion: I. germanica extract can successfully reverse spatial learning dysfunction in an experimental model of 
AD. Further neuro psyco-pharmacological studies are mandatory to reveal the mechanism of action of this natural 
remedy in the management of AD symptoms.   
 
Keywords: Alzheimer's disease, Iris germanica, spatial learning, escape latency, traveled distance, beta amyloid, 
common flag, traditional Persian medicine 
 
Introduction 
 
Today, in 2016, over 47 million people live with dementia worldwide. This population is rapidly growing and 
is estimated to increase to 131.5 million until the end of 2050 (Prince et al., 2016). 
Alzheimer's disease (AD) is an essential cause of dementia that is an irretrievable chronic neurodegenerative 
disease (Fodale et al., 2006). Major neuropathological characteristics of AD comprise extracellular insoluble senile 
amyloid beta (Aβ) accumulation in the form of protein plaques surrounded by dead or dying neurons, extensive 
neuronal loss, as well as hyperphosphorylation of tau proteins precipitated as intracellular neurofibrillary tangles 
(NFTs) (Iqbal et al., 2005; Selkoe, 2001). In addition, cholinergic deficiency, dysfunctional apoptosis and synaptic 
alterations in brain hippocampal areas and the entorhinal cortex, underlie the pathological basis for AD (Law et al., 
2001; Majlessi et al., 2012). 
Aβ is a pro-inflammatory highly toxic material which results in neuro-inflammation in the brain tissue (Tuppo 
and Arias, 2005). In the brain, inflammation is associated with stimulation of microglial cells which have a pivotal role 
in neurodegenerative processes including those occurring in AD (Thameem Dheen et al., 2007).  
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A growing body of experiments along with clinical evidence support the idea that elevated Aβ levels can be 
linked with impairment of cognition and can cause pathological events resulting in cognitive defects such as those 
identified in AD (Bharadwaj et al., 2009; Rodrigue et al., 2009). Oxidative stress markers and neuro inflammation 
possess a pivotal role in the initiation and development of the disease (Akiyama et al., 2000; Moreira et al., 2009). 
Although a wide range of studies has been performed for understanding the etiology and pathophysiology of AD, 
current treatment approaches with acetyl choline esterase inhibitors (AChEIs) are just symptomatic, performed for the 
management of cognitive symptoms including impairment in perception (Bassil and Grussberg, 2009; Neugroschl and 
Sano, 2009). Despite the ability of  these drugs in alleviating symptoms, they cannot inhibit disease development, the 
period of their pharmacological effect is restricted, and they also have several adverse effects such as gastrointestinal 
complications (Mimica and Presecki, 2009). The restrictions of current AD therapeutics have encouraged investigators 
to discover novel treatments. Current investigations are considering the preventive and/or disease-modifying drugs 
(Basil and Grussberg, 2009). A wide range of studies is performed to identify drugs that can decrease Aβ accumulation 
via affecting proteases, which modify Aβ formation, as well as increasing its clearance. 
Various medicinal plants, as well as their active components have been used in traditional and complementary 
therapeutic approaches to improve cognitive performance and managing other complications of AD (Howes et al., 
2003; May et al., 2009; Mukherjee et al., 2007). Iris germanica L. which is known as "Irsa" in traditional Persian 
medicine, can be widely found in various geographical regions all over the world and is cultivated for decorative 
purposes, as well (Rahman et al., 2003). Iris species are rich sources of isoflavonoids. Various isoflavones like 
irigenin, nigricin, irilone, and irisolidone were identified in I. germanica rhizome (Ibrahim et al., 2017; Roger et al., 
2012; Xie et al., 2013). In addition, benzene derivatives have been isolated from the methanolic extract of I. germanica 
(Asghar et al., 2010). Moreover, different sterols including sitosterol and stigmasterol have been reported from it 
(Ibrahim et al., 2012). The rhizomes have been used to manage some neurodegenerative disorders including AD in 
traditional Persian medicine (Choudhary et al., 2005). Several species of the genus Iris have been reported to exhibit a 
variety of biological functions including anti-bacterial, anti-ulcer and anti-inflammatory properties (Rahman et al., 
2003). To our knowledge, there is no scientific report on the beneficial effect of I. germanica on neurodegenerative 
disorders. Hence, this study was conducted to examine the effect of I. germanica extract on the spatial performance of 
rats in an experimental model of AD. 
 
Materials and Methods 
Animals 
 
Male Wistar rats with the weight range of 200–250 g were housed as five animals per cage with free access to 
food and water. Animals were kept in standard animal house condition including 12 h light/dark cycle and room 
temperature of 20–22 °C. All experimental procedures were performed based on the guidelines of Ethical Committee 
for the care and use of laboratory animals in Tehran University of Medical Sciences. 
 
Establishment of AD model 
Preparation of β-amyloid peptide1–42 (Aβ1–42) and fibrillation 
 
The Aβ1–42, supplied from Sigma-Aldrich (St. Louis, MO. USA), was dissolved, and the samples were kept 
at −20 °C until further experiment. Aβ1–42 solutions were prepared with the concentration of 100 ng/μl in phosphate 
buffered saline (PBS, 0.1 M) and incubated for a five-day period at 37 °C. On the day of the experiment, PBS was 
inserted to the solution and the final concentration of 50 ng/μl was obtained. 
 
Stereotaxic surgery 
 
Wistar rats were anesthetized via i.p. injection of 5 mg/kg xylazine and 90 mg/kg ketamine, and were fixed 
under stereotaxic device (Stoelting, USA). A suture was made along the midline. Then, the scalp was retracted, and the 
bregma area was washed and prepared for injection. 
Using a 1-μl Hamilton micro syringe, one microliter of Aβ or vehicle (sham group) was bilaterally injected in the CA1 
section of the hippocampus (50 ng/μl/side). The coordinates were based on the Paxinos and Watson rat brain atlas: 
incisor bar −3.3 mm, 3.8 mm posterior to the bregma, ±3.2 mm lateral to the sagittal suture and 2.7 mm down from top 
of the skull. Microinjections were applied over a slow period of 60 s (Eftekharzadeh et al., 2012). 
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Plant material and preparation of Iris aqueous extract 
 
I. germanica rhizomes were purchased from a local herbal store. A botanist authenticated the plant, and a 
voucher specimen (PMP-228) was deposited in the Herbarium of Department of Pharmacognosy, Faculty of 
Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.  
The rhizomes were cut into small pieces, washed in distilled water, air-dried at room temperature and milled 
into coarse particles.  
To obtain the aqueous extract, 100 g of fine plant powder was soaked in 100 ml distilled water and left for 24 
h in the refrigerator, and then boiled gently on the heater with the magnetic stirrer for approximately 6 h. Then, the 
extract was filtered using filter paper. The obtained filtrate was concentrated with a rotary evaporator and dried in a 
vacuum oven for 3 days at 40 °C. The extraction ratio was 20%. Finally, the prepared extract was stored in the 
refrigerator at 4 °C. 
 
Extract administration 
 
Animals were randomly put into five groups of 8 rats per each. Treatment groups were as followed: control 
group which were normal rats without induction of AD, Aβ group in which received Aβ (50 ng/side), iris 100 which 
received Aβ (50 ng/side) + Iris (100 mg/kg), iris 200 which received Aβ (50 ng/side) + Iris (200 mg/kg), and iris 400 
which received Aβ (50 ng/side) + Iris (400 mg/kg). The condensed aqueous Iris extract was suspended in distilled 
water. The day after surgery, animals in treatment groups received three different doses (100, 200 or 400 mg/kg) of the 
extract by gavage for 30 days. 
 
Morris water maze test (MWM) 
 
Thirty days after surgery, MWM training of rats in all experimental groups was started. The maze included a 
round black-colored water pool (136 cm diameter and 60 cm height), which was filled with 22±2 °C water to a depth 
of 40 cm. The pool was divided into four equal parts and a Plexiglas hidden platform, with 10 cm diameter, was placed 
1 cm under the water surface in the center of the target quadrant, which was the North-West part. The rats training 
continued for a 4-day period. Each day of training consisted of one block including four trials. Each of the trials was 
performed by putting the animal in one of the four quadrants of MWM. Rats had a 90 s period to swim in the pool and 
find the underwater platform. When an animal was not able to find the platform during this default period, it was 
guided to the platform by the experimenter. The animals had 20 s rest between two tandem trials and all trials were 
performed at the same time of the morning each day. The behavior and movement of rats were recorded using a video 
camera, linked to a computer, above the center of the maze. The test evaluating learning capabilities were performed at 
the days 31 to 34 after the post-training intrahippocampal injections of the drugs by calculating escape latency (time to 
reach the platform), traveled distance (the distance to find the platform), and swimming speed parameters. In order to 
assess post-training probe trial experiments, rats were trained for a period of four days after the recovery from surgery 
as previously described.  
Post-training probe trial tests were performed on day 35 Aβ injection to evaluate the occupancy and crossing 
of rats in the proximity of the target quadrant (the quadrant included hidden platform during training trials). During the 
probe trial test, the platform was removed from the pool, and Wistar rats were put in the pool in a part opposite to the 
target quadrant and permitted to freely swim for 90 s. 
Using the Ethovision tracking system (Noldus Information Technology, Wageningen, Netherlands), learning 
function and spatial memory retention were analyzed. 
 
Histopathological evaluations 
 
For the confirmation of Aβ plaque formation in rat brain, 35 days after Aβ injection, 5 animals (1 rat from 
each group) were euthanized and their brains were immersed in 4% paraformaldehyde for 24 h and fixative formalin 
%15 for 24-48 h. Then, an automated processor executed dehydration and paraffin embedding. The brain tissue was 
segmented and stained by Congo red based on the previous report (Wilcock et al., 2006).  
 
Results 
Effects of different treatments on traveled distance, escape latency and swimming speed average for all training 
days 
 
Figure 1 shows the traveled distance (a), the escape latency (b) and the swimming speed (c) for five treatment 
groups. Aβ protein resulted in a remarkable elevation of traveled distance (P<0.001) as well as escape latency 
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(P<0.001) in comparison to the control animals (Figure 1a, b). As shown in Figure 1, all parameters, except the 
swimming speed, improved in groups treated with Iris extract in comparison to Aβ group. Traveled distance was 
significantly reduced in all groups which received Iris compared with the Aβ injected group (P<0.001 for iris 100 and 
iris 200 and P<0.0001 for iris 400) (Figure 1a). The same results were attained in analyzing the escape latencies and 
Iris treated groups showed a significant decrease in escape latency compared to the Aβ group (P<0.001) (Figure 1b). It 
should be mentioned that, as shown in Figure 1c, no significant differences were observable in swimming speed 
between the treatment groups (P>0.05). 
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Figure 1: Effect of intrahippocampal injection of Aβ, Aβ plus Iris treated animals on (a) traveled distance, (b) escape 
latency to platform zone, and (c) swimming speed in MWM. Five groups of animals received bilateral infusion of 
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either phosphate buffered saline (control group), Aβ (50 ng/side), Aβ (50 ng/side) + Iris (100 mg/kg), Aβ (50 ng/side) 
+ Iris (200 mg/kg), Aβ (50 ng/side) + Iris (400 mg/kg). Each point shows the mean ± SEM for 6–8 rats. # Significantly 
different from Aβ injected group. *Significantly different from control group (P<0.05). **, ##: P<0.01; ***, ###: 
P<0.001; ****, ####: P<0.0001. 
 
 
Effects of different treatments on traveled distance, escape latency and swimming speed in training days 
 
Figure 2 shows the results of the behavioral tests for all days in different experimental groups. A statistically 
significant decrease in the traveled distance was observed on the 3rd and 4th days of the experiment in comparison to 
the first day in the control group (P<0.01 and P<0.0001 for the 3rd and 4th days, respectively). Herbal treated groups 
in all doses demonstrated a significant reduction in traveled distance (P<0.0001 in day 4 compared with day 1). No 
significant differences between traveled distances on the second, third and fourth days were observed, compared to the 
first day for the Aβ group (Figure 2a).  
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Figure 2: Effect of oral administration of Iris on (a) traveled distance and (b) escape latency to platform zone in 
MWM for all training days for five groups. Five groups of animals received bilateral infusion of either phosphate 
buffered saline (control group), Aβ (50 ng/side), Aβ (50 ng/side) + Iris (100 mg/kg), Aβ (50 ng/side) + Iris (200 
mg/kg), Aβ (50 ng/side) + Iris (400 mg/kg). Each point shows the mean± SEM for 6–8 rats. * Signiﬁcantly difference 
between the ﬁrst and other training days. (P<0.05); **: P<0.01; ***: P<0.001; ****: P<0.0001. 
 
A similar trend was achieved after the analyzing of escape latency values. Escape latency time significantly 
reduced on the 3rd and 4th days of the study compared to the first day in the control group (P<0.01 and P<0.0001). 
Likewise, the treatment group that received Iris 100 mg/kg, 200 mg/kg or 400 mg/kg, demonstrated a remarkable 
reduction in escape latency on the 4th experimental day compared with the first training day (P<0.0001). Same as the 
traveled distance, no statistically significant difference was observed between escape latencies on 2nd, 3rd and 4th 
days compared to the first day for the group that only received Aβ (Figure 2b).  
a 
b 
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Finally, results of the swimming speed for all of the treatment groups showed no significant effect by neither Aβ nor 
Iris administration. 
 
Effects of different treatments on post training probe trial test 
  
Figure 3 illustrates the outcomes of post-training probe trial test. Results showed that this parameter 
significantly reduced in Aβ group compared with the control group (P<0.01). Treatment of animals with I. germanica 
extract significantly elevated the time spent in the target quadrant in comparison with Aβ injected group (P<0.01)  
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Figure 3: Post-training probe trial tests, which were performed 21 days after drug infusion for all groups. In this test, 
we removed the platform, left animals for 90 s in the water and measured the time that animals spent in the target 
quadrant. Five groups of animals received bilateral intrahippocampal infusion of either phosphate buffered saline 
(control group), Aβ (50 ng/side), Aβ (50 ng/side) + Iris (100 mg/kg), Aβ (50 ng/side) + Iris (200 mg/kg), Aβ (50 
ng/side) + Iris (400 mg/kg). Each point shows the mean ± SEM for 6–8 rats. *Significantly different from control 
group. # Significantly different from Aβ injected groups (P<0.05). **, ##: P<0.01; ***, ###: P<0.001. 
 
Histological tests 
 
For detection of Aβ plaques in the hippocampus, Congo red staining was performed on the tissue. As shown 
in Figure 4, the staining confirmed the formation of Aβ plaque in brains of the Aβ-injected animals in the hippocampal 
area. Optical microscope Images showed a significant decrease in the number of Aβ plaques in all three groups treated 
with Iris germanica extract. 
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Figure 4: Congo red staining to detect beta-amyloid plaques in the hippocampus in five group: (a) phosphate buffered 
saline (control group), (b) Aβ (50 ng/side), (c) Aβ (50 ng/side) + Iris (100 mg/kg), (d) Aβ (50 ng/side) + Iris (200 
mg/kg), (f) Aβ (50 ng/side) + Iris (400 mg/kg). 
 
Discussion 
 
Alzheimer's disease (AD) is known as an age-related neurodegenerative disorder that is linked with oncoming 
loss of cognitive capacity and mild memory impairment (Lustig et al., 2003). The neuropathologic features of the 
disease including extracellular senile plaques, intracellular neurofibrillary tangles as well as neuronal loss in some 
brain areas including hippocampal area (Majlessi et al., 2012). One of the key events observed in the 
neuropathogenesis of AD is Aβ protein deposition and the amyloid plaques formation of in the brain (Wang et al., 
2014). Aβ is a 39–43 amino acid peptide that is the result of proteolysis of amyloid precursor protein by β and γ-
secretases and the Aβ 1–42 is the most neurotoxic fragment of this peptide (Lambert et al., 1998). In this experiment, 
intrahippocampal injection of the aggregated Aβ1-42 significantly induced impairments in cognitive ability in the rat. 
In our study, we have found that aqueous extract of I. germanica L. can improve the cognitive function (learning and 
memory) in AD model rat induced by Aβ1- 42 that tested by MWM. A wide range of clinical and preclinical studies 
has suggested the therapeutic role of medicinal plants and their active constituents in the management of neurological 
disorders including neurodegenerative diseases (Bahramsoltani et al., 2015; Farzaei et al., 2016; Shahpiri et al., 2016).   
In a brain affected by AD, the severity of memory dysfunction and cerebral deposition of Aβ is associated 
with a marked cholinergic dysfunction. The decrease of ACh in specific brain areas leads to learning and memory 
deficits (Kar et al., 2004). Increased AChE activity and decreased choline acetyltransferase (ChAT) activity may result 
in the reduction of Ach level. Many studies have suggested that inhibition of neuronal AChE activity in experimental 
models leads to increase in Ach level and consequently improve the cognitive function (Chattipakron et al., 2007; 
Nakdook et al., 2010; Ingkaninan et al., 2003). AchE inhibitory activity of I. germanica var. florentina have been 
demonstrated in vitro (Ullah et al., 2016) . 
it has been found that I. germanica has potent antioxidant and anti-inflammatory properties (Nadaroglu et al., 
2007; Rahman et al., 2003). Inflammation and oxidative damage are two factors that implicate in AD pathogenesis. So, 
we can suggest that these two mechanisms are involved in the anti-Alzheimer effect of this medicinal plant.  
Also, one animal study revealed that Iris extract can lower serum level of cholesterol which is associated with the 
promotion of amyloidogenesis by regulating β- and γ-secretase activity (Choudhary et al., 2005). Hence, modulating 
amyloidogenesis mediated by lowering the level of cholesterol is another neuropharmacological mechanism of I. 
germanica in improving learning and memory abilities of AD (Bodovitz and Klein, 1996; Frears et al., 1999; Wolozin, 
2001). 
These findings suggest that Iris could attenuate the progression of AD. The mechanism is related to AchE 
inhibitory, cholesterol lowering, antioxidant and anti-inflammatory properties. Therefore, Iris germanica may be 
considered as a new therapeutic option for AD.  
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Conclusion  
 
 Iris germanica extract was used to treat experimental model of AD for the first time. The results showed that 
Iris markedly enhanced the cognitive function of Aβ induced-AD rat in the behavioral test. Further 
neuropsycopharmacological studies are mandatory to reveal the perfect mechanism of action of this natural remedy in 
the management of AD symptoms. In addition, the phytochemical investigation is suggested for identifying the main 
active constituents of I. germanica responsible for the therapeutic effect on AD behavioral symptoms. 
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